OpGen

OpGen P/CF

The P/CF (Price-to-Cash-Flow Ratio) of OpGen (OPGN) as of Oct 22, 2026 is -308.57. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -75.00 — a change of 311.43% (lower).

P/CF

-308.57

YoY

311.43%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of OpGen is 2025 -308.57 . P/CF (Price-to-Cash-Flow Ratio) of OpGen was 2024 -75.00 . It decreases by 311.43% lower compared to the previous year.

The OpGen P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-32.98 USD
Jan 1, 2019
-31.74 USD
Jan 1, 2020
-15.61 USD
Jan 1, 2021
-17.00 USD
Jan 1, 2022
-17.86 USD
Jan 1, 2023
-25.51 USD
Jan 1, 2024
-75.00 USD
Jan 1, 2025
-308.57 USD
The OpGen P/CF history
YEARP/CFYoY
-308.57+311.43%
-75.00+194.05%
-25.51+42.81%
-17.86+5.03%
-17.00+8.93%
-15.61-50.82%
-31.74-3.75%
-32.98+29.17%
-25.53+20.60%
-21.17-17.23%
-25.58-62.28%
-67.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

P/CF (Price-to-Cash-Flow Ratio) of OpGen is -308.57 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of OpGen changed from -75.00 to -308.57, representing a 311.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) OpGen since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — OpGen

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — OpGen